Drug Topics- August 11, 2008

72 DRUG TOPICS AUGUST 11, 2008 www.drugtopics.com VIEWPOINT Walter Way, R.Ph., M.D., and Fred Mayer, Pharm.D., MPH Medicare Part D revisions sorely needed new year is coming, and with it a new administration in Washington; a new Congress; and a new, more skeptical look at Medicare Part D. Congressman Henry Waxman (D, Calif.) is already planning hearings on Medicare Part D for February 2009. Waxman heads the House Committee on Oversight and Government ReWhen Rxs form. When his 13-member bipartisan comcannot be filled, mittee looked at Part D in mid-2007, it left it is pharmacists no doubt about its findings. “The Private who must suffer Medicare Drug Plans: High Expenses and Low Rebates Increase the Cost of Medicare the anger and Drug Coverage” was both the primary conclusion and the title of the committee frustration of report. patients who are The Waxman committee released five primary findings: unable to obtain • Part D incurs excessive administrative care under Part D. expenses. • Part D plans have not negotiated any significant manufacturer discounts or rebates for the U.S. government. • Part D plans receive rebates on full-price drug purchases made by plan beneficiaries caught in coverage gaps. Plans do not pass the savings on to affected beneficiaries. • Part D plan formularies have generated price increases that average 8% to 10% annually. • Part D plans have a mixed record in promoting generic drug products that could significantly reduce the cost burden on beneficiaries and the federal government. The Waxman committee report is a superb analysis of the defective Part D program. Its investigation highlights the deficiencies of this ill-conceived and poorly designed program. But its conclusions are not universally accepted. A May 2008 report for the Medicare Payment Advisory Commission (MedPAC) found that a majority of patients like Part D, with physicians close behind. Pharmacists are less satisfied and for good reason. Pharmacists bear the responsibility of fixing the multitude of problems that Part D has created for patients and prescribers. When problems cannot be fixed and prescriptions cannot be filled, it is pharmacists who must suffer the anger, frustration, and sometimes hospitalization and A death of patients who are unable to obtain appropriate pharmaceutical care under Part D. Pharmacists are not alone in recognizing the problems of Part D. The MedPAC report found that patients and prescribers are unhappy with the coverage gap, formulary exclusions, and abysmal customer service from some Part D plans. Medicare Part D is not a cohesive benefit program. It is a clutter of hundreds of profit-driven entities. Part D rewards plans for skimping on pharmaceutical care provided to millions of Americans in order to boost plan profits. The basic design that incorporates multiple formularies, donut-hole coverage gaps, and a plethora of prescription drug programs, pharmacy benefit managers, and insurance administrations defies administrative oversight. We applaud Congressman Waxman’s decision to revisit and revise Medicare Part D. We recommend that the new Administration and Congress target five areas. 1. The bewildering multiplicity of administrative entities created by Part D makes it virtually impossible for even a well-informed beneficiary to evaluate alternative plans. 2. Individual plan formularies are not comparable. Formularies are driven by plan financial considerations, not by patient healthcare needs or rational prescribing. 3. The Centers for Medicare and Medicaid Services (CMS) has inadequate staff, funding, and expertise to oversee Part D programs and entities. 4. Beneficiaries and providers cannot effectively challenge formulary selection or coverage determinations in a timely manner. Many beneficiaries and their prescribers do not even realize that they have a right to contest coverage determinations. 5. Pharmacy and therapeutics committees are not accessible to patients or providers and operate with virtually no oversight by CMS or any other third party. It is past time to redesign the Part D program so that it can function as intended to lower Medicare prescription drug costs while improving patient outcomes with more effective drug therapy. Walter Way is professor emeritus of anesthesia and molecular pharmacology at the University of California, San Francisco. He is also medical director of Pharmacists Planning Service Inc. (PPSI), San Rafael, Calif. Fred Mayer is past president of the California Public Health Association and CEO of PPSI. http://www.drugtopics.com

Table of Contents Feed for the Digital Edition of Drug Topics- August 11, 2008

Drug Topics- August 11, 2008 Contents Latebreakers Letters DEA Proposes Rule To Allow Electronic Prescriptions for Controlled Substances Merger, Medicare Reform Could Mean Broader E-Prescribing Adoption New Combination Pill Approved for Type 2 Diabetes New Eczema Guildlines Promote Use of Emollients, Then Topical Corticosteroids Agencies Flush Original Strategies in Favor of Promoting Drug Take-Back Programs JP at Large: You Laughing at Me? Pharmacists Find Themselves at Mercy of Prior Authorization State Law Requiring PBM Transparency See Some Gains, Some Losses Global Counterfeiting Still Growing, Says U.S. Commerce Official FDA Saftey Page: Prophylthiouracil Still Confused with Purinethol (mercaptopurine) New Products Bring Lice Treatment to a Head NACDS Marketplace Showcases New Product that Fill Unmet Needs Update on Respiratory Tract Infections Execs Share War Stories About Adopting Technology in their Stores New Products Advertisters Index Classified Viewpoint: Medicare Part D Revisions sorely needed

For optimal viewing of this digital publication, please enable JavaScript and then refresh the page. If you would like to try to load the digital publication without using Flash Player detection, please click here.